Human Tissue Act (UK)

The Human Tissue Act 2004 was introduced following public inquiries into the unauthorised retention of organs and tissue from deceased patients — most notably at Bristol Royal Infirmary (the Kennedy Inquiry into paediatric cardiac surgery) and at Alder Hey Children’s Hospital in Liverpool — which found that thousands of organs had been kept without the knowledge or consent of families during the 1980s and 1990s. Parliament’s response was to replace consent as an informal courtesy with consent as the express, statutory precondition for almost everything that can lawfully be done with human tissue, and to create a dedicated regulator to license and inspect the organisations that store it. The Act received Royal Assent in 2004 and its main provisions, together with the licensing regime, came fully into force on 1 September 2006.

What counts as “relevant material” and a “scheduled purpose”

The Act does not regulate every use of human biological material — it applies to activities involving “relevant material” carried out for one of a defined list of “scheduled purposes”. Section 53 defines relevant material as material consisting of, or including, human cells, with specific exclusions: gametes and embryos outside the body (separately regulated under the Human Fertilisation and Embryology Act 1990), and hair and nail from a living person. Schedule 1 lists the scheduled purposes, which include anatomical examination, post-mortem examination, public display, transplantation, and — the purpose most relevant to research administration — “research in connection with disorders, or the functioning, of the human body.”

Two practical consequences follow directly from this scope. First, storing or using hair or nail clippings from a living person, or working only with information/data derived from tissue rather than the physical material itself, sits outside the Act even though it originates from a human body. Second, a specific statutory carve-out means storage of material consisting only of extracted DNA or serum does not require a Human Tissue Authority licence, even though it is still “relevant material” for consent purposes.

The “appropriate consent” framework

Consent is the Act’s organising principle. For activities involving the deceased, appropriate consent must generally be given in writing; for the living, the common-law standard of appropriate consent applies (research involving adults who lack capacity is separately governed by the Mental Capacity Act 2005). Consent can be project-specific — authorising use for one named study — or broader, authorising storage and future, as-yet-unspecified research use, which is the model most generic-consent research tissue banks rely on. There are narrow exceptions where the Act does not itself require consent to store or use tissue for research: existing holdings collected before the Act’s licensing provisions came into force, and tissue from the living that has been anonymised (so that the researcher cannot identify the individual it came from) for a project that has itself received ethics approval. The Human Tissue Authority’s Code A (Guiding Principles and the Fundamental Principle of Consent) and Code E (Research) set out how consent should be obtained and documented in practice, including for generic biobanking consent.

The Human Tissue Authority’s licensing role for research tissue banks

The Act established the Human Tissue Authority (HTA) — operational from April 2006 — as the licensing and inspecting regulator for scheduled-purpose activities. For research specifically, an HTA storage licence is generally required to store relevant material for the scheduled research purpose, and premises such as research tissue banks and biobanks that hold tissue on an ongoing basis for future, generically-consented research are the clearest example of licensable activity. The HTA’s Research Licensing Standards and Guidance group licence conditions under four headings — Consent, Governance and quality systems, Traceability, and Premises, facilities and equipment — and licensed sites are subject to periodic inspection.

There is an important, narrower exemption for a single research project: storage of relevant material does not require its own HTA licence where the storage is for “qualifying research” — research that has been given a favourable opinion by a recognised Research Ethics Committee (REC), or is a specific research project for which that ethical approval is pending. This is the mechanism by which most individual, project-scoped studies (rather than standing generic-consent tissue banks) avoid needing a separate storage licence: REC approval of the specific protocol substitutes for HTA licensing of that specific storage activity. The HTA is explicit that it does not license, or have any role in approving, the “use” of tissue in an individual research project or its scientific/ethical merits — that judgement sits with the REC, not the regulator.

How this interacts with REC / research ethics review

This is the point most often misunderstood by teams new to UK human-tissue research: HTA regulation and REC ethical review are two distinct, independently-running legal regimes that commonly apply to the same piece of research, not one process wearing two names. The REC’s job is to assess whether a specific research project is ethically justified and whether consent arrangements for participants are adequate; the HTA’s job is to license and inspect the physical infrastructure — the premises, governance systems, and traceability controls — under which relevant material is stored, independent of any judgement about a given project’s merits. A licensed research tissue bank operating under a generic ethical opinion can typically release material to individual downstream research projects without each of those projects separately seeking its own REC approval, provided the release fits within the terms of the bank’s existing consent and ethical opinion — but a bank cannot substitute for REC review of a project outside those terms, any more than REC approval substitutes for a required HTA storage licence.

This distinct-but-overlapping pattern is structurally similar to how the US Common Rule (45 CFR 46) and the HIPAA Privacy Rule operate side by side on the same study — IRB/REC review governs research ethics and consent, while HIPAA independently governs use and disclosure of protected health information, and neither approval satisfies the other’s requirements. Research administrators coordinating UK tissue-based studies should expect to track HTA licensing status and REC approval as two separate compliance records, not a single combined sign-off, and should confirm which one — or both — a given activity actually needs before assuming either is sufficient on its own.

Geographic scope: England, Wales, and Northern Ireland only

The Human Tissue Act 2004 applies in England, Wales, and Northern Ireland. It does not apply in Scotland, which instead operates under its own, separate Human Tissue (Scotland) Act 2006, regulated differently (Scottish ethical approval structures recognise a form of reciprocal arrangement so that a favourable opinion from a Scotland-based REC can support UK-wide Human Tissue Act compliance for research conducted elsewhere in the UK, but the underlying Scottish statute and its consent model are not identical to the 2004 Act). Anyone running a multi-site UK study spanning Scotland and the rest of the UK should treat this as two distinct legal frameworks to check, not a single UK-wide statute with regional variation.

Practical implications for research administrators

• Confirm early whether a project involves “relevant material” for a “scheduled purpose” at all — data-only research, or research using only excluded material (hair, nail, gametes/embryos, DNA/serum-only collections), sits outside the Act’s licensing regime even though ethics review and data protection law will usually still apply.
• Treat HTA licensing status and REC/ethics approval as two separate things to check and document, not one combined gate — see the interaction section above.
• For a standing research tissue bank intended to support multiple future, not-yet-defined projects, budget for an HTA storage licence application and ongoing inspection compliance in addition to the bank’s own generic ethical opinion.
• For a single, project-scoped study relying on the qualifying-research exemption, keep clear documentation that REC approval for that specific project is in place (or genuinely pending) — that documentation is what substitutes for a separate storage licence, and its absence is a common audit finding.
• Check jurisdiction before assuming UK-wide applicability: England/Wales/Northern Ireland fall under the 2004 Act and HTA; Scotland falls under the Human Tissue (Scotland) Act 2006.

Frequently asked questions

What is the Human Tissue Act 2004?

It is the UK statute (England, Wales, and Northern Ireland) that makes appropriate consent a legal requirement for removing, storing, and using human tissue and organs from the living and the deceased for a defined list of purposes, including research, and that establishes the Human Tissue Authority as the licensing regulator for those activities.

Does the Human Tissue Act apply in Scotland?

No. Scotland is covered by the separate Human Tissue (Scotland) Act 2006, which has its own consent model. A multi-site UK study spanning Scotland needs to check both frameworks rather than assuming one UK-wide statute applies everywhere.

Does every research tissue bank need an HTA storage licence?

Not automatically. A standing bank storing tissue under generic consent for future, unspecified research generally does need an HTA licence. A single project relying on the “qualifying research” exemption — storage tied to a specific project with a favourable REC opinion, or an opinion that is genuinely pending — does not need its own separate licence for that storage. DNA-only or serum-only storage is also excluded from the licensing requirement.

Is HTA approval the same as REC/ethics approval?

No. They are legally distinct regimes that often both apply to the same study. The HTA licenses and inspects the premises and governance systems used to store relevant material; it does not assess or approve the scientific or ethical merits of an individual research project — that is the REC’s role.

What is “appropriate consent” under the Act?

The legal standard of consent the Act requires before relevant material can be removed, stored, or used for a scheduled purpose. It must generally be in writing for activities involving the deceased, and follows common-law consent principles for the living, with narrow exceptions (e.g., anonymised tissue from the living used in an ethically-approved study).

What human material falls outside the Act’s scope?

Gametes and embryos outside the body (regulated separately under the Human Fertilisation and Embryology Act 1990) and hair and nail from a living person are expressly excluded from the definition of “relevant material,” so activities involving only that material are not regulated by the Human Tissue Act.